胆固醇偶联miR-29b通过γ-珠蛋白启动子去甲基化在Townes镰状细胞贫血小鼠模型中诱导胎儿血红蛋白表达
本研究在Townes镰状细胞贫血(SCA)小鼠中探讨间歇性皮下注射胆固醇偶联miR-29b(Chol-miR-29b)诱导胎儿血红蛋白(HbF)表达的能力。结果显示Chol-miR-29b治疗使γ-珠蛋白mRNA水平显著升高、F细胞百分比增加,脾组织γ-珠蛋白基因启动子DNMT3A蛋白和5-甲基胞嘧啶水平降低,RNA测序支持癌基因沉默和抑癌基因激活。作者认为每日皮下剂量Chol-miR-29b可诱导HbF表达,凸显其在SCA临床开发中的潜力。
要点
- Chol-miR-29b治疗的SCA小鼠行为正常、体重增加,无外周血细胞计数毒性。
- Chol-miR-29b治疗后γ-珠蛋白mRNA水平显著升高,F细胞百分比增加。
- 脾组织证实γ-珠蛋白基因启动子DNMT3A蛋白和5-甲基胞嘧啶水平降低。
核心结论
- 每日皮下剂量Chol-miR-29b可诱导HbF表达,凸显其在SCA临床开发中的潜力。
研究设计与样本
- 在Townes镰状细胞贫血(SCA)小鼠模型中开展的研究,给予间歇性皮下胆固醇偶联miR-29b(Chol-miR-29b)治疗。
- 检测包括自动全血细胞计数及分类、网织红细胞计数、逆转录定量PCR定量γ-珠蛋白和βS-珠蛋白mRNA水平、流式细胞术测定HbF阳性细胞(F细胞)百分比、甲基化测定5-甲基胞嘧啶水平以及RNA测序分析不同处理条件下的基因表达变化。
主要发现
- 接受Chol-miR-29b的SCA小鼠行为正常、体重增加,无外周血细胞计数毒性。
- Chol-miR-29b治疗后γ-珠蛋白mRNA水平显著升高,F细胞百分比增加。
- 脾组织证实γ-珠蛋白基因启动子DNMT3A蛋白和5-甲基胞嘧啶水平降低。
- RNA测序分析支持Chol-miR-29b引起癌基因沉默和抑癌基因激活。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cholesterol-conjugated miRNA has emerged as a viable system for preventing small molecule degradation in plasma with low toxicity and high delivery efficiency. We previously established that miR-29b induces fetal haemoglobin (HbF) in Townes sickle cell anaemia (SCA) mice using a continuous infusion mini-osmotic pump. Herein, we expanded the scope of our work to determine the ability of intermittent subcutaneous cholesterol-conjugated miR-29b (Chol-miR-29b) to induce HbF expression in SCA mice. Blood was collected for automated complete blood counts with differential, reticulocyte count and γ-globin and βS-globin mRNA levels quantified by reverse transcription-quantitative PCR; flow cytometry measured the percentage of HbF-positive cells (F-cells). Methylation assays determined 5-methylcytosine levels, and RNA sequencing changes in gene expression for different treatment conditions. SCA mice receiving Chol-miR-29b exhibited normal behaviour and weight gain without peripheral blood count toxicity. The γ-globin mRNA levels significantly increased, and F-cell percentages were enhanced after Chol-miR-29b treatment. Subsequently, spleen tissue confirmed decreased DNMT3A protein and 5-methylcytosine levels in the γ-globin gene promoter. RNA-seq analysis supports oncogene silencing and tumour suppressor gene activation by Chol-miR-29b. These data demonstrate that a daily subcutaneous dose of Chol-miR-29b induces HbF expression, highlighting its potential for clinical development in SCA.
引用
- Palani CD, Smith A, Cao X, et al. Cholesterol-conjugated miR-29b induces fetal haemoglobin expression via γ-globin promoter demethylation in the Townes mouse model for sickle cell anaemia. Br J Haematol. 2025. PMID: 40320590. doi:10.1111/bjh.20107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。